Literature DB >> 26596571

Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [(11)C]MK-8193.

Eric D Hostetler1, Hong Fan2, Aniket D Joshi2, Zhizhen Zeng2, Waisi Eng2, Liza Gantert2, Marie Holahan2, Xianjun Meng2, Patricia Miller2, Stacey O'Malley2, Mona Purcell2, Kerry Riffel2, Cristian Salinas2, Mangay Williams2, Bennett Ma3, Nicole Buist4, Sean M Smith5, Paul J Coleman6, Christopher D Cox6, Brock A Flores6, Izzat T Raheem6, Jacquelynn J Cook2, Jeffrey L Evelhoch2.   

Abstract

PURPOSE: A positron emission tomography (PET) tracer for the enzyme phosphodiesterase 10A (PDE10A) is desirable to guide the discovery and development of PDE10A inhibitors as potential therapeutics. The preclinical characterization of the PDE10A PET tracer [(11)C]MK-8193 is described. PROCEDURES: In vitro binding studies with [(3)H]MK-8193 were conducted in rat, monkey, and human brain tissue. PET studies with [(11)C]MK-8193 were conducted in rats and rhesus monkeys at baseline and following administration of a PDE10A inhibitor.
RESULTS: [(3)H]MK-8193 is a high-affinity, selective PDE10A radioligand in rat, monkey, and human brain tissue. In vivo, [(11)C]MK-8193 displays rapid kinetics, low test-retest variability, and a large specific signal that is displaced by a structurally diverse PDE10A inhibitor, enabling the determination of pharmacokinetic/enzyme occupancy relationships.
CONCLUSIONS: [(11)C]MK-8193 is a useful PET tracer for the preclinical characterization of PDE10A therapeutic candidates in rat and monkey. Further evaluation of [(11)C]MK-8193 in humans is warranted.

Entities:  

Keywords:  Carbon-11; Enzyme; Imaging; Monkey; Occupancy; PDE10A; PET; Phosphodiesterase 10A; Rat

Mesh:

Substances:

Year:  2016        PMID: 26596571     DOI: 10.1007/s11307-015-0910-0

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  29 in total

1.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

Authors:  Izzat T Raheem; Michael J Breslin; Christine Fandozzi; Joy Fuerst; Nicole Hill; Sarah Huszar; Monika Kandebo; Somang H Kim; Bennett Ma; Georgia McGaughey; John J Renger; John D Schreier; Sujata Sharma; Sean Smith; Jason Uslaner; Youwei Yan; Paul J Coleman; Christopher D Cox
Journal:  Bioorg Med Chem Lett       Date:  2012-07-27       Impact factor: 2.823

4.  The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.

Authors:  Renee C Gentzel; Dawn Toolan; Rhonda Roberts; Amy Jo Koser; Monika Kandebo; James Hershey; John J Renger; Jason Uslaner; Sean M Smith
Journal:  Neuropharmacology       Date:  2015-06-02       Impact factor: 5.250

5.  Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain.

Authors:  Zhude Tu; Jinda Fan; Shihong Li; Lynne A Jones; Jinquan Cui; Prashanth K Padakanti; Jinbin Xu; Dexing Zeng; Kooresh I Shoghi; Joel S Perlmutter; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2011-01-22       Impact factor: 3.641

6.  Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.

Authors:  Christopher D Cox; Eric D Hostetler; Broc A Flores; Jeffrey L Evelhoch; Hong Fan; Liza Gantert; Marie Holahan; Waisi Eng; Aniket Joshi; Georgia McGaughey; Xiangjun Meng; Mona Purcell; Izzat T Raheem; Kerry Riffel; Youwei Yan; John J Renger; Sean M Smith; Paul J Coleman
Journal:  Bioorg Med Chem Lett       Date:  2015-06-01       Impact factor: 2.823

7.  In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.

Authors:  Kazunori Suzuki; Akina Harada; Eri Shiraishi; Haruhide Kimura
Journal:  J Pharmacol Exp Ther       Date:  2014-12-18       Impact factor: 4.030

8.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

Authors:  M Yamazaki; W E Neway; T Ohe; I Chen; J F Rowe; J H Hochman; M Chiba; J H Lin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

9.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

10.  AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.

Authors:  Hang Chen; Dianna Lester-Zeiner; Jianxia Shi; Silke Miller; Charlie Glaus; Essa Hu; Ning Chen; Jessica Able; Christopher Biorn; Jamie Wong; Ji Ma; Klaus Michelsen; Geraldine Hill Della Puppa; Tim Kazules; Hui Hannah Dou; Santosh Talreja; Xiaoning Zhao; Ada Chen; Shannon Rumfelt; Roxanne K Kunz; Hu Ye; Oliver R Thiel; Toni Williamson; Carl Davis; Amy Porter; David Immke; Jennifer R Allen; James Treanor
Journal:  J Pharmacol Exp Ther       Date:  2014-12-11       Impact factor: 4.030

View more
  2 in total

1.  In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs.

Authors:  Barry R Campbell; Dinko Gonzalez Trotter; Catherine D G Hines; Wenping Li; Manishkumar Patel; Weisheng Zhang; Jeffrey L Evelhoch
Journal:  ILAR J       Date:  2016-12

2.  Comparison of [11C]TZ1964B and [18F]MNI659 for PET imaging brain PDE10A in nonhuman primates.

Authors:  Hui Liu; Hongjun Jin; Xuyi Yue; Junbin Han; Hao Yang; Hubert Flores; Yi Su; David Alagille; Joel S Perlmutter; Gilles Tamagnan; Zhude Tu
Journal:  Pharmacol Res Perspect       Date:  2016-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.